anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Epstein-Barr (EBV) is a human γ-herpesvirus that undergoes both a productive (lytic) cycle and a non-productive (latent) phase. The virus establishes enduring latent infection in B lymphocytes and productive infection in the oral mucosal epithelium. Like other herpesviruses, EBV expresses its genes in a coordinated pattern during acute infection. Unlike others, it replicates its DNA during latency to maintain the viral genome in an expanding pool of B lymphocytes, which are stimulated to divide upon infection. The reactivation from the latent state is associated with a productive gene expression pattern mediated by virus-encoded transcriptional activators BZLF-1 and BRLF-1. EBV is a highly transforming virus that contributes to the development of human lymphomas. Though viral vectors and mRNA platforms have been used to develop an EBV prophylactic vaccine, currently, there are no vaccines or antiviral drugs for the prophylaxis or treatment of EBV infection and EBV-associated cancers. Natural products and bioactive compounds are widely studied for their antiviral potential and capability to modulate intracellular signaling pathways. This review was intended to collect information on plant-derived products showing their antiviral activity against EBV and evaluate their feasibility as an alternative or adjuvant therapy against EBV infections and correlated oncogenesis in humans.
The invention discloses an oil-in-water type sodium nitroprusside-garlic oil nanoemulsion antihypertensive drug. The nanoemulsion antihypertensive drug has a particle size in a range of from 15.7 to 50.4 nm and an average particle size of 32.9 nm. Raw materials for the drug comprise, by mass percentage, 1% to 20% of sodium nitroprusside, 10% to 35% of surfactant, 0 to 25% of cosurfactant and 1% to 20% garlic oil, with the balance being distilled water, wherein the sum of the mass percentage of the raw materials is 100%. Nanoemulsion provided in the invention has small and uniformly-distributed emulsion droplet particles, low viscosity and good fluidity. In the dosage form of nanoemulsion, the water-soluble drug sodium nitroprusside and fat-soluble garlic oil are organically combined together, which improves the solubility and permeability of garlic oil and the stability and efficacy of sodium nitroprusside. When the dosage form of nanoemulsion is prepared from sodium nitroprusside and garlic oil, the advantages of both sodium nitroprusside and garlic oil are combined; therefore, an antihypertensive effect of the drug provided in the invention is obviously improved, the half life of the drug is prolonged, and administration frequency is reduced.
As done in the R34, the comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education (Refs). Families in the comparison arm will receive the same intervention components as the intervention arm, but these will be focused on child reading rather than nutrition. Parents will send a video of themselves reading with a child, receive 3 home visits and 48 text-messages as well as newsletters for each visit. Instead of receiving cooking materials during the second home visit, they will receive books to read with their children.
PROBLEM TO BE SOLVED: To obtain a detergent compsn. which provides a refreshing feeling when used and is excellent in detergency by compounding specified amts. of titanium oxide and a polyethylene powder. SOLUTION: 0.01-1.0 wt.% titanium oxide pref. having an average particle size of 0.01-0.5 μm and 0.5-10.0 wt.% polyethylene powder pref. having an average particle size of 1-50 μm are compounded, pref. at a wt. ratio of (1:5)-(1:50). Both rutile and anatase titanium oxide can be used. Materials usually used for detergents, such as a humectant (e.g. glycerin), an anionic surfactant, a lipophilic nonionic surfactant, a hydrophilic nonionic surfactant, an amphiphatic surfactant, and a cationic surfactant, can be used arbitrarily. A thickener, a bactricide, an antioxidant, etc., may also be incorporated.
The invention discloses a flexible film and a preparation method thereof. The flexible film comprises a photo-thermal response layer, a mechano-electric response layer and a photo-thermal response layer which are sequentially arranged from top to bottom. The mechano-electric response layer is a polyvinyl alcohol/glycine mechano-electric response layer, and the photo-thermal response layer is a collagen/conductive polymer photo-thermal response layer. The polyvinyl alcohol/glycine force electricity response layer is a sandwich structure of polyvinyl alcohol-glycine-polyvinyl alcohol; the collagen/conductive polymer photo-thermal response layer takes a collagen network crosslinked by a crosslinking agent as a framework, takes a conductive polymer as a modified material, the surface presents a double exposure morphology of the collagen and the conductive polymer, and composite conductive fibers in which the conductive polymer is composited by taking the collagen as the framework exist inside. The flexible film has the functions of photo-thermal stimulation response and passive electric stimulation response, has good force-electricity conversion performance, electrochemical performance, photo-thermal performance and biocompatibility, and can be degraded in physiological environment. The preparation method is simple in preparation process, easy to realize and suitable for popularization and application.
BACKGROUND AND AIMS: Research into the relationship between an Energy-adjusted Diet-Inflammatory Index (E-DII) and a wider health-related biomarkers profile is limited. Much of the existing evidence centers on traditional metabolic biomarkers in populations with chronic diseases, with scarce data on healthy individuals. Thus, this study aims to investigate the association between an E-DII score and 30 biomarkers spanning metabolic health, endocrine, bone health, liver function, cardiovascular, and renal functions, in healthy individuals.
METHODS AND RESULTS: 66,978 healthy UK Biobank participants, the overall mean age was 55.3 (7.9) years were included in this cross-sectional study. E-DII scores, based on 18 food parameters, were categorised as anti-inflammatory (E-DII < -1), neutral (-1 to 1), and pro-inflammatory (>1). Regression analyses, adjusted for confounding factors, were conducted to investigate the association of 30 biomarkers with E-DII. Compared to those with an anti-inflammatory diet, individuals with a pro-inflammatory diet had increased levels of 16 biomarkers, including six cardiometabolic, five liver, and four renal markers. The concentration difference ranged from 0.27 SD for creatinine to 0.03 SD for total cholesterol. Conversely, those on a pro-inflammatory diet had decreased concentrations in six biomarkers, including two for endocrine and cardiometabolic. The association range varied from -0.04 for IGF-1 to -0.23 for SHBG.
CONCLUSION: This study highlighted that a pro-inflammatory diet was associated with an adverse profile of biomarkers linked to cardiometabolic health, endocrine, liver function, and renal health.
The invention discloses a vaccine of a largemouth black bass iridovirus, a preparation method and application thereof. The vaccine of the largemouth black bass iridovirus is a protein encoded by a nucleotide sequence shown as SEQ ID No. 1. The method is to construct plasmid pET21a-LMBV and transform escherichia coli BL21 (DE 3), induce expression and crush cells, and then recover and purify recombinant proteins, namely the vaccine of the iridovirus of the largehead jewfish. The recombinant protein rMCP can be mixed with an adjuvant, and the obtained vaccine mixed solution has the function of immunoprotection against the largehead jewfish iridovirus LMBV. The vaccine of the iridovirus of the largehead jewfish has stable immune effect, higher relative protection rate and high-efficiency protection, and can be applied to the protection of fish fries and adult fish against the infection of the iridovirus of the largehead jewfish in the largehead jewfish breeding process.
The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
The present invention relates to a pain treatment medicine-ningtongling for treating cancer pain, which belongs to the technical field of medicine. The present invention is mainly made by that pillbug, paniculate swallowwort roots, white peony alba, turmeric root tuber and licorice are evenly mixed, and are dried at the temperature of 30 to 60DEGC, the mediicnes are pulverized by a disintegrator secondarily, and sterilization, bottling and sealing are carried out. The present invention has the action of qi movement, blood activation, nutrient system regulation and pain relief, and is used for treating cancer pain. The present invention has the characteristics of powerful and enduring analgesic effect, immediate effect, medicine resistance, convenient taking, etc. Because the present invention is made by the adoption of the pure traditional Chinese medicines, the present invention does not contain toxicity, and is a narcotic Chinese medicinal plant. The present invention has the advantages of no toxic or side effect on a human body, simple manufacture process and low cost; the present invention overcomes the medicinal addiction of anodynes, such as sauteralgyl, morphine, sand coffe, etc., which are frequently used at present in the world.
Patients receive NXP800 according to assigned treatment schedule. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or PET at baseline and on study. Patients may optionally undergo ultrasound-guided liver biopsy and/or collection of blood samples on study and during follow up.
Manual in-line stabilisation is used to immobilise the neck during endotracheal intubation in patients undergoing cervical spine surgery to prevent secondary spinal cord damage. This makes visualisation of the glottis difficult with conventional laryngoscopy which can be overcome with videolaryngoscope. CMAC Videolaryngoscope has the conventional blade (C blade) and the highly angulated D blade which was introduced to aid in difficult airway. This study was done to compare the ease of tracheal intubation using the conventional C blade and the D blade of CMAC videolaryngoscope in patients undergoing cervical spine surgery.

Methodology: After Institutional Ethics Committee approval and obtaining informed consent, 68 patients undergoing elective cervical spine surgery were randomised into 2 groups - C (intubated with C blade) or D (intubated with D blade) (n=34 each) by computer generated randomisation. After induction of general anaesthesia, manual in-line stabilisation of the cervical spine was achieved and intubation was attempted by experienced anaesthesiologist with the C blade or D blade according to the group. The time taken for successful intubation, time taken for optimum glottic visualisation, the number of attempts, additional manouvres required for successful intubation and the incidence of complications were compared.
Spermatozoa harbour a complex and environment-sensitive pool of small non-coding RNAs (sncRNAs)1, which influences offspring development and adult phenotypes1-7. Whether spermatozoa in the epididymis are directly susceptible to environmental cues is not fully understood8. Here we used two distinct paradigms of preconception acute high-fat diet to dissect epididymal versus testicular contributions to the sperm sncRNA pool and offspring health. We show that epididymal spermatozoa, but not developing germ cells, are sensitive to the environment and identify mitochondrial tRNAs (mt-tRNAs) and their fragments (mt-tsRNAs) as sperm-borne factors. In humans, mt-tsRNAs in spermatozoa correlate with body mass index, and paternal overweight at conception doubles offspring obesity risk and compromises metabolic health. Sperm sncRNA sequencing of mice mutant for genes involved in mitochondrial function, and metabolic phenotyping of their wild-type offspring, suggest that the upregulation of mt-tsRNAs is downstream of mitochondrial dysfunction. Single-embryo transcriptomics of genetically hybrid two-cell embryos demonstrated sperm-to-oocyte transfer of mt-tRNAs at fertilization and suggested their involvement in the control of early-embryo transcription. Our study supports the importance of paternal health at conception for offspring metabolism, shows that mt-tRNAs are diet-induced and sperm-borne and demonstrates, in a physiological setting, father-to-offspring transfer of sperm mitochondrial RNAs at fertilization.
INTRODUCTION: Adrenal hemorrhage (AH) is a rare condition and severe cases can lead to acute adrenal insufficiency with potentially life-threatening consequences. AH can be caused by a variety of etiologic factors, including systemic lupus erythematosus and antiphospholipid syndrome (APS). The early identification and treatment of these patients improves their prognosis.
OBJECTIVE: The aims of this study were to analyze and summarize the clinical characteristics of systemic lupus erythematosus patients with AH.
METHODS: The clinical characteristics of 6 systemic lupus erythematosus patients complicated with AH admitted to Peking Union Medical College Hospital and Beijing Shijitan Hospital from May 2004 to April 2022 were retrospectively analyzed.
RESULTS: The diagnosis of AH was based on computed tomography (CT) findings. Two patients had bilateral lesions, and the other 4 patients had unilateral lesions. The symptoms of adrenal insufficiency were observed in 2 patients. The frequent presenting symptoms were abdominal pain, lower abdominal distension, vomiting, weakness, fever, arthrodynia, and skin rash. Four patients had APS. Five patients (4 patients with APS and 1 patient without APS) had thromboembolic events. All patients received glucocorticoid and immunosuppressant therapy. Five patients were treated with anticoagulant therapy. Follow-up imaging examinations showed a partial or total regression of the lesions after treatment.
CONCLUSIONS: In the proper clinical setting, having high clinical suspicion for AH, early diagnosis and timely management is crucial to avoid life-threatening adrenal insufficiency. Key Points • AH is a rare condition and severe cases may lead to death. It can be caused by a variety of etiologic factors, including SLE. • In patients with SLE, especially combined with APS, if they complain of abdominal pain, particularly when common gastrointestinal involvement is difficult to explain, a high index of clinical suspicion is needed for the diagnosis of AH. • Early identification of AH in SLE patients can improve their prognosis.
Patients must meet the MDS criteria for Parkinson's disease. Disease duration: any Age 30 years or older at time of PD diagnosis.
Percutaneous transluminal coronary angioplasty and drug eluting stent implantation according to local standard of care, including optimization techniques (e.g. post-dilatation) which are left at operators' discretion, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.
Participants received a single oral dose of 500 milligram (mg) of test Glucophage Immediate Release (GIR) tablet Sino-American Shanghai Squibb (SASS)/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (Merck Santé in Semoy (MSS)/France) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
<P>PROBLEM TO BE SOLVED: To obtain an energy-reinforcing agent composition capable of being taken easily without fearing adverse reaction and without having anxiety, and effective for decreased sexual impuls and sterility.  <P>SOLUTION: This energy-reinforcing agent contains octopine as an active ingredient, and especially useful for the improvement of desire for sexual intercourse and improvement of pregnancy ratio. The energy-reinforcing component is preferably prepared for an oral ingestion preparation. The octopine may be contained as an extract extracted from 1 kind or ≥2 kinds of fishery organisms selected from fishes and shellfishes of bivalva or cephalopods. As the fishes and shellfishes of the bivalva or cephalopods, 1 kind or ≥2 kinds fishery organisms selected from a scallop, clam, short-necked clam and cuttlefish are preferable.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention discloses a Chinese materia medica preparation which is used for treating vitiligo, and comprises human medicine and externally applied agent. The human medicine is prepared from raw materials of Chinese herbal medicine of the following weight ratio: 10 to 25 portions of radix salviae miltiorrhizae, 5 to 15 portions of angelica, 5 to 10 portions of Astraolylis lancea formalyrata, 5 to 10 portions of notoginseng, 5 to 10 portions of Angelica dahurica, 10 to 25 portions of fructus ligustri lucidi, 10 to 25 portions of prepared rhizome of rehmannia, 10 to 25 portions of Psoraleae, 10 to 25 portions of litharge, 5 to 10 portions of black sesame seeds, 5 to 10 portions of cynamorlum, 5 to 10 portions of coridius. The externally applied agent is prepared from raw materials of Chinese herbal medicine of the following weight ratio: 30 to 90 portions of roots of fructus momordicae, 20 to 60 portions of agrimony, 30 to 90 portions of litharge, 10 to 60 portions of ginger, and 5 to 30 portions of calomel. The preparation adopts the traditional Chinese medicinal herbs as raw materials based on the theory of traditional Chinese medicine. When in use for treating the vitiligo, the preparation emphasizes using poisons as antidotes and maintains simultaneous treatment and replenishment. Thus the preparation guarantees the curative effects and achieves the curative purpose from the superficial and the basic levels. And recrudescence can hardly occur after the vitiligo is cured.
There are two, 45-60 minute sessions of didactic educational intervention related to promoting awareness for sexual health involving contraception and STI prevention. The first session occurs at the enrollment of the study, the second at 3 month follow-up.
OBJECTIVE: This study was undertaken to assess the effectiveness/tolerability of adjunctive cenobamate, variations in the load of concomitant antiseizure medications (ASMs) and predictors of clinical response in people with focal epilepsy.
METHODS: This was a retrospective study at 21 centers participating in the Italian Expanded Access Program. Effectiveness outcomes included retention and responder rates (≥50% and 100% reduction in baseline seizure frequency). Tolerability/safety outcomes included the rate of treatment discontinuation due to adverse events (AEs) and their incidence. Total drug load was quantified as the number of concomitant ASMs and total defined daily dose (DDD). Concomitant ASMs were also classified according to their mechanism of action and pharmacokinetic interactions to perform explorative subgroup analyses.
RESULTS: A total of 236 subjects with a median age of 38 (Q1-Q3 = 27-49) years were included. At 12 months, cenobamate retention rate was 78.8% and responders were 57.5%. The seizure freedom rates during the preceding 3 months were 9.8%, 12.2%, 16.3%, and 14.0% at 3, 6, 9, and 12 months. A higher percentage of responders was observed among subjects treated with clobazam, although the difference was not statistically significant. A total of 223 AEs were recorded in 133 of 236 participants, leading to cenobamate discontinuation in 8.5% cases. At 12 months, a reduction of one or two concomitant ASMs occurred in 42.6% and 4.3% of the subjects. The median total DDD of all concomitant ASMs decreased from 3.34 (Q1-Q3 = 2.50-4.47) at baseline to 2.50 (Q1-Q3 = 1.67-3.50) at 12 months (p < .001, median percentage reduction = 22.2%). The highest rates of cotreatment withdrawal and reductions in the DDD were observed for sodium channel blockers and γ-aminobutyric acidergic modulators (above all for those linked to pharmacokinetic interactions), and perampanel.
SIGNIFICANCE: Adjunctive cenobamate was associated with a reduction in seizure frequency and in the burden of concomitant ASMs in adults with difficult-to-treat focal epilepsy. The type of ASM associated did not influence effectiveness except for a favorable trend with clobazam.
One open-label, multicenter, Phase 2 study was conducted testing imatinib mesylate in diverse populations of patients with life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. This study included 14 patients with Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia (HES/CEL). HES patients were treated with 100 mg to 1,000 mg of imatinib mesylate daily. The ages of these patients ranged from 16 to 64 years. A further 162 patients with HES/CEL aged 11 to 78 years were reported in 35 published case reports and case series. These patients received imatinib mesylate at doses of 75 mg to 800 mg daily. Hematologic response rates are summarized in Table 24. Response durations for literature patients ranged from 6+ weeks to 44 months.

Table 24: Response in HES/CEL
Pregabalin capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
Participants will receive subcutaneous (SC) golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may enter in an open-label (OL) extension period to receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area).